P2C invests $250K in Anvesana to help advance mRNA therapies

To help advance new treatments for hemophilia and other blood disorders, Pathway to Cures (P2C) has invested $250,000 in Anvesana, a company working to develop therapies based on RNA biology. “Anvesana is delighted to be working with Pathway to Cures to develop therapeutics that will bring life altering…

RNA Gene Therapy Seen to Effectively Treat Hemophilia A Mouse Model

A new type of gene therapy that uses RNA instead of DNA led to rapid and prolonged production of therapeutic levels of factor VIII (FVIII) in a mouse model of hemophilia A, a study reported. The study, “Treatment of…

Scientists Use New Protein Replacement Therapy to Treat Hemophilia B in Mice

Scientists managed to treat hemophilia B using a new method of protein replacement therapy in a mouse model of the condition.